Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).
D.Festi, F.Lodato, G.Mazzella, A.Colecchia (2008). Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression. NEW YORK : Springer.
Effect of combined IFN-Alpha/Ribavirin Treatment in HCV disease-related progression
FESTI, DAVIDE;LODATO, FRANCESCA;MAZZELLA, GIUSEPPE;COLECCHIA, ANTONIO
2008
Abstract
Chronic HCV hepatitis is a progressive disease; if not treated it progress towards liver cirrhosis, hepatocellular carcinoma and/or liver insufficiency. Different antiviral treatments are now available, whose success rate ranging from 20 to 65% of the patients, depending on factors related to the virus (viral load, genotype, etc) or to the host (gender, age, time of infections, precence of comorbidities).File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
